Purple Biotech Ltd. American Depositary Shares (PPBT)

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clin…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

10

Website

purple-biotech.com/

Fundamentals

1-day range

$1.63$1.73

Market cap

$2.39M

P/E (trailing)

—

P/E (forward)

-1.64

EPS (trailing)

$-0.02

Dividend yield

—

Beta

0.29

Avg. volume

224.9K

Dividend pay date

August 21, 2020

Purple Biotech Ltd. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• PPBT

  Purple Biotech Ltd. American Depositary Shares

  $1.68

  ▲ 1.20%
  Market cap $2.39MP/E —
  $1$3.9
• OGEN

  Oragenics Inc. Common Stock

  $0.5296

  ▼ 0.08%
  Market cap $2.39MP/E —
  $0.4801$1.45
• SBFM

  Sunshine Biopharma Inc. Common Stock

  $1.16

  ▼ 8.66%
  Market cap $2.48MP/E —
  $1.01$24.3
• ARTL

  Artelo Biosciences Inc. Common Stock

  $0.6619

  ▲ 0.14%
  Market cap $2.59MP/E —
  $0.52$28.14
• MTNB

  Matinas Biopharma Holdings Inc. Common Stock

  $0.1966

  ▼ 1.70%
  Market cap $1.93MP/E —
  $0.178$2.14
• SXTC

  China SXT Pharmaceuticals Inc. Class A Ordinary Shares

  $3

  ▼ 13.29%
  Market cap $2.94MP/E —
  $3.1$83,758
• CDT

  CDT Equity Inc. Common Stock

  $1.69

  ▼ 10.37%
  Market cap $1.81MP/E —
  $1.62$2,928

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

75.7K

Total value held

$305.6K

Institutional holders

15